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PCN174
ImmuNe CheCkPoINt INhIbItors as adjuvaNts: future ChalleNges for 
PrICINg aNd reImbursemeNt
Wieffer H.M., McKendrick J., Petropoulos A., Saltman D.
PRMA Consulting, Fleet, UK
OBJECTIVES: Adjuvant cancer therapy is additional treatment administered after the 
primary treatment (usually surgery) to lower the risk of recurrence. The mechanism 
of action of the recently developed immune checkpoint inhibitors suggests they 
have potential as adjuvant therapies: by their action in enhancing the anti-tumor 
immune response, residual tumor cells may be eliminated. In this study, we identi-
fied potential challenges to pricing and reimbursement (P&R) assessment of these 
drugs as adjuvant given the likely high cost of these innovative agents. METHODS: 
We searched clinicaltrials.gov to identify current trials of immune checkpoint inhibi-
tors as adjuvant therapies. We then searched the website of the UK health technol-
ogy assessment agency, NICE, for appraisals of adjuvant cancer therapies, identified 
the corresponding evaluations by PBAC (Australia) and the SMC (Scotland) on these 
agencies’ websites, and identified key challenges. RESULTS: We identified nine trials 
with an immune checkpoint inhibitor used as adjuvant therapy, only one of which 
was Phase 3. Six NICE appraisals of pharmacological agents used as adjuvants were 
identified, all of which had also been assessed by PBAC and the SMC. Particular 
areas of concern in evaluations were the extrapolation of disease-free survival to 
overall survival, and the balance between safety and benefit in disease prevention. 
Restrictions were imposed in several decisions on the duration of adjuvant treat-
ment and the risk status of patients, dependent on the available clinical evidence. 
So far, adjuvant therapies have rarely tested acceptable cost-effectiveness thresh-
olds. CONCLUSIONS: Development of immune checkpoint inhibitors as adjuvant 
therapies is still at an early stage, but consideration of the economic and clinical 
case for these drugs will be needed to ensure successful P&R. Experience with the 
evaluation of high-cost therapies in this context is limited, so engagement will be 
needed between manufacturers and agencies to define the required evidence and 
willingness to pay.
PCN175
PredICtors of a PosItIve CaNCer drug fuNd deCIsIoN
Jaksa A., Liden D., Ho Y.
Context Matters, New York, NY, USA
OBJECTIVES: Since 2011, the United Kingdom has set aside £200 million per year 
through the Cancer Drug Fund (CDF) to pay for oncology treatments not reviewed or 
approved by NICE. The CDF scores drugs on progression-free survival (PFS), overall 
survival (OS), quality of life (QoL), safety, unmet need, and strength of evidence 
(SE). The scores determine if the drug will be included on the CDF priority list. 
This analysis attempts to determine the weight each score has on the reimburse-
ment decision. METHODS: All available CDF decision summaries post April 2013 
were analyzed. Scores for PFS, OS, QoL, safety, unmet need and SE were extracted 
from each decision summary. The CDF decision was classified as positive (recom-
mended) or negative (do not recommend). Deferred decisions or drugs not scored 
were excluded. A probit model was used to estimate the probability of a positive 
decision based on the scores. RESULTS: Drugs filling an unmet need, or drugs with 
the similar/improved toxicity predicted a positive reimbursement decision per-
fectly. Drugs with significantly worse toxicity predicted a negative decision perfectly. 
Because of perfect prediction, these variables (including SE) were excluded from 
the model. Of the remaining variables in the model (PFS, OS, and QoL), only OS was 
significant. An increase in OS was related to a higher probability of getting a positive 
reimbursement decision (p= .017). If OS was less than two months, the probability of 
a positive decision was 41%, but the probability of a positive decision increases to 
99% for 6-7 months OS. CONCLUSIONS: Unmet need and similar/improved toxic-
ity are perfect predictors of a positive CDF decision. If a drug do not fill an unmet 
need or has worse toxicity, improvements in OS increase the probability of a posi-
tive decision. If the drug improves OS by 6-7 months there is a 99% probability of 
a positive decision.
PCN176
barbeC(eu)d oNCology market aCCess â€ “ how bbQ Pulled Pork Is 
sImIlar to euroPeaN P&r NegotIatIoNs
Swilling N, Altier J.
Simon-Kucher and Partners, Cambridge, MA, USA
OBJECTIVES: In this study, we look at the market access delays caused by lengthy 
pricing and reimbursement negotiations in the EU5. In addition, we look at the 
results of those pricing negotiations compared to the US, and the outcome with 
regards to access for specific subpopulations. METHODS: We examined over 20 
oncology NMEs with EMA approval over the last three years and looked at the 
date of initial price publication in each market, HTA agency outcomes (where 
available), and price level at launch to compare the length of the price negotiation 
and price levels across EU markets as well as with the United States. RESULTS: 
Coming to a negotiated agreement for reimbursement in France, Italy, and Spain 
typically takes over a year, but there is no recognizable trend by market. In addi-
tion, oncology pricing in the EU5 has been found to be significantly lower than the 
US by an average of 30-40%. Lastly, we found that HTA agencies such as in France 
or Germany increasingly look at sub-group analysis and find a lack of benefit in 
some patient sub-populations. CONCLUSIONS: The secret to good pulled pork is 
low temperatures and long cooking time. With low prices and long negotiations, 
EU payers have found a recipe that is working well for them, but likely giving 
oncology manufacturers indigestion. An explosion in oncology launches over the 
past years have left payers scrutinizing the added value of new products and we 
are seeing payers demonstrating little interest in making those drugs available 
to patients quickly or at an attractive price. A realignment towards a more high 
risk but high reward approach of looking for true innovation will hopefully lead 
to better patient outcomes and higher profits for pharmaceutical and biotech 
manufacturers.
OBJECTIVES: The study aims to quantify the expected impacts of different cancers 
through multiplying the incidence rate by loss-of-QALE (quality-adjusted life expec-
tancy), with QALY (quality-adjusted life year) as the common unit, to aid prevention 
policy decisions. METHODS: 464,722 patients with pathologically verified cancer 
registered in the Taiwan Cancer Registry during 1998-2009 were used to estimate 
lifetime survival through Kaplan-Meier estimation combined with a semi-para-
metric method. A convenience sample for measuring the utility value with EQ-5D 
was conducted with 11,453 cancer patients, with the results then multiplied by the 
survival functions to estimate QALE. The loss-of-QALE was calculated by subtracting 
the QALE of each cancer cohort from the life expectancy of the corresponding age- 
and gender-matched reference population. The cumulative incidence rates from age 
20 to 79 (CIR20-79) were calculated to estimate the lifetime risk of cancer for each 
organ-system. RESULTS: Liver and lung cancer were found the highest expected 
lifetime health impacts in males and females, or expected lifetime losses of 0.97 and 
0.41 QALYs that could be averted, respectively. While the priority changes for preven-
tion based on expected health impacts were slightly different for females based on 
standardized mortality rates, those of males involve a broader spectrum, including 
oral, colorectal, esophageal and stomach cancer. CONCLUSIONS: The integration 
of incidence rate with loss-of-QALE could be used to represent the expected losses 
that could be averted by prevention, which may be useful in prioritizing strategies 
for cancer control.
PCN172
QualIty of evIdeNCe suPPortINg INClusIoN of PharmaCogeNomIC 
bIomarkers IN ProduCt labels of fda aPProved oNCology theraPIes
Jha RK, Gupta J, Kapoor A, Mazumder D
Optum Global Solutions, Noida, India
OBJECTIVES: Pharmacogenomic biomarkers aid in predicting drug response and 
adverse drug reactions. Drug label provides information about these biomarkers; 
however the quality of evidence regarding biomarker use is unclear. Thus, we 
investigated the FDA-approved drug labels for the availability and quality of evi-
dence supporting the biomarkers use in conjunction with targeted therapies in dif-
ferent cancers. METHODS: We searched the US FDA website to identify the labels 
providing information on the pharmacogenomic biomarkers of the targeted can-
cer therapies. The Evaluation of Genomic Application in Practice and Prevention 
Working Group’s guideline was used to assess the clinical validity and utility of the 
referenced studies. The available evidence was graded as convincing, adequate, or 
incomplete. We also assessed the completeness of studies and recommendation 
in the label. RESULTS: Fifty-three drug-biomarker combinations were identified, 
encompassing 42 unique drugs and 23 unique biomarkers. Combinations were 
most frequently identified in breast cancer (26%), chronic myeloid leukemia (15%), 
and colorectal cancer (11%). Half of the supporting evidence in drug labels (51%) 
were not graded with convincing validity (i.e., the ability to predict the pheno-
type of interest) and more than half (60%) were incomplete pertaining to utility 
(i.e., the ability to improve measurable clinical outcomes). Complete information 
of the referenced clinical studies was included in only 11% labels, whereas 62% 
labels provided partial information. The treatment recommendations about clini-
cal decision were based on the drug’s mechanism of action in 75% of the labels 
and on drug-biomarker association in 21% of drug labels. Also, the biomarker’s 
prediction of improved drug response and contraindications was provided in 77% 
and 23% labels, respectively. CONCLUSIONS: Majority of the labels lacked con-
vincing validity and utility regarding biomarker use. As biomarkers may enhance 
clinical care, it has become extremely important for inclusion and rational 
use of pharmacogenomic information in drug labels, for optimized decision- 
making.
PCN173
Carbohydrate INtake aNd breast CaNCer rIsk IN afrICaN amerICaN 
aNd euroPeaN amerICaN womeN IN the womeN’s CIrCle of health 
study
Johnson N.M.1, Bandera E.2
1ICON PLC, Morristown, NJ, USA, 2Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 
USA
OBJECTIVES: The overall incidence of breast cancer is lower in African American 
(AA) women in comparison to European American (EA) women; however AA women 
are more likely to die of the disease. National data has reported that compared to 
EA women, AA women have a poorer diet quality and are also among the highest 
consumers of added sugar. This analysis aims to explore the association of carbo-
hydrate intake and breast cancer risk among AA and EA women. METHODS: We 
evaluated the association in a case-control study including cases (breast cancer 
positive) and controls (cancer negative). Food consumption was collected using 
a Food Frequency Questionnaire. Multivariable logistic regression controlling for 
relevant breast cancer risk factors was used to calculate Odd Ratios (OR) and 95% 
Confidence Intervals (CI). RESULTS: Our sample size was 3148. Overall, EA women 
who consumed larger amounts of total carbohydrates (highest quartile) had a sig-
nificantly decreased risk of breast cancer compared to those who consumed lower 
amounts of total carbohydrates (lowest quartile) OR= 0.60; 95% CI: 0.43-0.83. In strati-
fied analyses, a stronger inverse relationship was noted amongst premenopausal 
EA women for total carbohydrates (OR= 0.48; 95% CI: 0.30-0.78) and added sugars 
(OR= 0.56; 95% CI: 0.35-0.89). Additionally in EA women with ER+ tumors, there 
was a significantly decreased risk of breast cancer for those who consumed larger 
amounts of total carbohydrates. For AA women, we found no evidence of an associa-
tion for total carbohydrates, glycemic load or added sugars. CONCLUSIONS: This 
study suggested an inverse association between carbohydrate consumption and 
breast cancer risk in EA women, particularly for those premenopausal and with 
ER+ tumors. However, we could not establish and association between carbohydrate 
consumption and breast cancer risk in AA women. Moreover, the specific types of 
carbohydrates and food sources need be studied for both EA and AA women to bet-
ter understand the association.
A220  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
PCN181
oPtImIsINg market aCCess of CaNCer drugs IN CaNada: a study of 
eCoNomIC revIews by the PaN-CaNadIaN oNCology drug revIew 
(PCodr) exPert CommIttee
Qu K.Q.1, Jiang Y.2, Gauthier A.2
1Amaris, Toronto, ON, Canada, 2Amaris, London, UK
OBJECTIVES: pCODR was established in 2010 to guide drug funding decisions through 
assessing the clinical, patient perspectives and cost-effectiveness (CE) information of 
new drugs. A considerable number of oncology drugs do not get recommended or get 
conditional recommendation. This study aims to analyse the comments provided in 
pCODR final recommendations and act as a guidance for manufacturers to improve 
the preparation of pCODR submissions. METHODS: A review of pCODR assessments 
was completed evaluating all recommendations made available between May 2012 
and December 2014 (N= 36) relating to 29 oncology drugs. The comments regarding 
CE estimates were extracted and analysed based on the assessments made available 
on the website. RESULTS: In the reviewed recommendations, 3 drugs received a posi-
tive unconditional recommendation (8%), 26 received a positive recommendation, 
conditional on the cost-effectiveness being improved to an acceptable level (72%) 
and 7 were not recommended for funding (20%). Comments on CE estimates were 
analysed and summarised, the most prevalent comments received included lengthy 
time horizon (n= 13), uncertainty (clinical benefits, large variability in the estimates, 
ICER sensitive to changes in overall survival) (n= 11), lack of clinical evidence (n= 9), 
inadequate model structure (n= 5), invalid clinical assumptions (n= 5) and the effects 
of potential wastage on ICER (n= 3). CONCLUSIONS: This review suggests that in order 
to minimise comments that might hinder a favourable recommendation, manufac-
turers need to focus on demonstrating the CE of a drug over a time period in which 
parameters are more certain (e.g. trial horizon), as well as trying to generate clinical 
evidence to prove benefits of a drug beyond trial period. The investigators are cur-
rently evaluating other aspects of the review deliberative framework (clinical benefit, 
patient-based values and adoption feasibility) with the aim to develop a more com-
prehensive guideline for manufacturer’s future submissions.
PCN182
use of moleCular testINg PrIor to fIrst-lINe erlotINIb theraPy 
amoNg medICare PatIeNts wIth stage Iv NoN-small Cell luNg CaNCer
Romanus D.1, Cutler D.1, Keating N.L.1, Lennes I.T.2, Lamont E.1, Gazelle G.S.2, Landrum M.B.1
1Harvard University, Boston, MA, USA, 2Massachusetts General Hospital, Boston, MA, USA
OBJECTIVES: The extent to which individual lung cancer patients undergo guide-
line-recommended molecular testing in routine care prior to initiation of first-line 
erlotinib is not known. Prevalence and factors associated with testing and erlotinib 
therapy were determined in Stage IV non-small cell lung cancer (NSCLC). METHODS: 
We identified incident cases diagnosed between 2007-2009 using SEER-Medicare 
data. Multivariable models were used to identify factors independently associated 
with (1) molecular testing and (2) receipt of first-line erlotinib therapy. RESULTS: 
Only 6.5% (500/7,678) were treated with first-line erlotinib and of those, only 8.6% 
underwent a molecular test. Testing and erlotinib therapy were independently 
associated with phenotypic enrichment using correlates of epidermal growth fac-
tor receptor (EGFR) mutations (female gender, Asian ethnicity, non-squamous-cell 
histology). Older age, Medicaid enrollment, and admission to hospice decreased like-
lihood of testing but increased probability of erlotinib therapy. CONCLUSIONS: Vast 
majority of NSCLC patients did not undergo molecular testing prior to treatment. 
Clinical enrichment criteria were influential in patient selection for erlotinib therapy 
and testing, but these attributes do not adequately discriminate between EGFR 
mutation positive and wild type tumors. Provider education and payer mandates 
to submit test results before reimbursement for targeted therapies may encourage 
guideline-recommended implementation of these technologies.
PCN183
oNCology drugs reCeIvINg breakthrough theraPy desIgNatIoN: 
ClINICal trIal CharaCterIstICs, drug PrICINg, aNd aPProval ProCess
Park Y.1, Vegesna A.2, Ray D.3, Tsang Y.4
1University of Maryland College of Pharmacy, Baltimore, MD, USA, 2Thomas Jefferson University, 
Philadelphia, PA, USA, 3Rutgers University, Piscataway, NJ, USA, 4University of Maryland 
Baltimore, Baltimore, MD, USA
OBJECTIVES: The Food and Drug Administration (FDA) grants breakthrough therapy 
designation (BTD) to facilitate faster approval of drug products are intended to treat 
a serious or life-threatening condition or provide substantial improvement over 
existing therapies. The purpose of this review is to compare time to approval, treat-
ment cost and key clinical design characteristics of BTD drugs to non-BTD drugs 
in oncology. METHODS: This narrative review used publicly reported data from 
drug manufacturers’ and FDA websites to examine all oncology drugs approved 
between November 2013 and December 2014. Median time-to-approval was assessed 
for new molecular entities (NMEs) and monthly treatment cost was calculated for 
approved indications based on wholesale acquisition cost (WAC) from Analysource. 
Approved oncology drugs were categorized as BTD and non-BTD drugs for com-
parison. RESULTS: A total of 25 FDA indications for oncology drugs were approved 
from November 2013 to December 2014. Nine indications were granted BTD, while 
16 were approved through non-BTD pathways. For NMEs, median time from phase 
1 trial initiation to indication approval was 2 times longer for non-BTD drugs (3414 
days) compared to BTD drugs (1732 days). Pivotal trials had a median sample size 
of 173 participants and 213 participants for BTD and non-BTD drugs, respectively. 
For BTD drugs, pivotal trials were 44% phase 2, 44% single-arm, and 89% open-label 
studies. For non-BTD drugs, pivotal trials were 44% phase 2, 28% single-arm, and 69% 
open-label studies. Median treatment cost was $9,249 per month for BTD drugs and 
$10,099 per month for non-BTD drugs. CONCLUSIONS: The BTD approval pathway 
has offered a considerably shorter time-to-approval for oncology drugs. Trials lead-
ing to approval for BTD drugs had a higher proportion of single-arm and open-label 
studies compared to non-BTD drugs. Our findings suggest that oncology drugs with 
BTD are not related to higher treatment cost.
PCN177
ImPaCt of tolerabIlIty ProfIles oN hta deCIsIoN makINg IN oNCology
Kreeftmeijer J.1, Ryan J.2, Van Engen A.1, Heemstra L.1
1Quintiles Consulting, Hoofddorp, The Netherlands, 2AstraZeneca, Cheshire, The Netherlands
OBJECTIVES: To highlight the impact of tolerability profiles on Health Technology 
Assessment (HTA) decision making in non-small cell lung cancer (NSCLC), ovarian 
cancer and prostate cancer from three European HTA agencies. METHODS: HTA 
assessments on NSCLC, ovarian cancer and prostate cancer products marketed since 
2011 were selected from HAS (France), G-BA (Germany) and NICE (UK). 14 reports on 
NSCLC, 5 on ovarian cancer and 14 on prostate cancer were selected for in-depth 
analysis. RESULTS: In the UK, safety profiles of the investigated drugs did not seem 
to have major impact on the recommendation. It was however seen that drugs with 
a good safety profile were more often recommended. Low impact of safety outcomes 
on the final decision from NICE was, for example, seen in the assessment of afatinib, 
where a significant increase in serious adverse events did not negatively impact the 
recommendation because clinical benefits outweighed safety concerns. Safety data 
and patient-relevance of endpoints is of high importance in Germany. A beneficial 
safety profile resulted in a higher benefit rating, whereas a negative safety profile 
lowered the G-BA rating. Case examples are evaluations of afatinib and crizotinib, 
where a negative safety profile lowered the benefit rating. Efficacy outcomes were 
weighted against safety outcomes in all assessments in France. An unfavourable 
safety profile appeared to have a negative impact on the ASMR rating from HAS, 
while a favorable profile did not have a positive impact. An example is the assess-
ment of cabazitaxel, where the safety data presented at the initial submission was 
unfavorable, resulting in a lower ASMR rating (IV), however a resubmission with 
additional safety data resulted in a higher rating (III). CONCLUSIONS: Different EU 
payers seem to have a different view on safety profiles, with the highest impact 
seen in Germany and the lowest impact seen in the UK.
PCN179
hIerarChy of ClINICal eNdPoINts IN hta deCIsIoN makINg IN 
oNCology
Kreeftmeijer J.1, Ryan J.2, Van Engen A.1, Heemstra L.1
1Quintiles Consulting, Hoofddorp, The Netherlands, 2AstraZeneca, Cheshire, The Netherlands
OBJECTIVES: To highlight the hierarchy of clinical endpoints in Health Technology 
Assessment (HTA) decision making in NSCLC, ovarian cancer and prostate cancer 
from three European HTA agencies. METHODS: HTA assessments on non-small cell 
lung cancer (NSCLC), ovarian cancer and prostate cancer products marketed since 
2011 were selected from HAS (France), G-BA (Germany) and NICE (UK). 14 reports on 
NSCLC, 5 on ovarian cancer and 14 on prostate cancer were selected for in-depth 
analysis. In addition ASCO and ESMO guidelines were reviewed for recommenda-
tions around endpoints. RESULTS: HTA agencies base their decisions on the signifi-
cance of the presented outcomes, but an analysis of NSCLC assessments showed 
that when the effect sizes in overall survival (OS) and progression-free survival 
(PFS) were deemed to be clinically irrelevant, recommendations were less positive. 
Significant improvements in OS and PFS can still be rejected in the UK because of 
unacceptable cost-effectiveness. Assessments demonstrating improvements only 
in PFS were most of the time rejected. Significant improvements in OS were asso-
ciated with a higher ASMR rating in France. Assessments with improvements in 
surrogate outcomes, including PFS and overall response rate, were also accepted. 
OS and quality of life (QoL) are the main outcomes contributing to the benefit rat-
ing in Germany. A combination of OS and QoL improvements was associated with a 
higher G-BA benefit rating. When OS or QoL data were absent, the benefit rating was 
lower. CONCLUSIONS: OS data is considered the gold standard for clinical benefit in 
oncology, but surrogate outcomes and QoL benefits were also accepted when non-
significant OS results were seen. In addition, it seems that statistical significance in 
itself is not enough, as payers want to see a clinical meaningful difference. Further 
research in pancreatic, breast and colon cancer, for which thresholds for clinical 
relevance have been published recently, could validate these results.
PCN180
Is there aN ImPaCt of the orPhaN desIgNatIoN IN oNCology oN 
market aCCess IN euroPe?
Boiziau S.C.
EMAUD, Claude Bernard Lyon 1 University, Villeurbanne cedex, France
OBJECTIVES: Orphan drugs (ODs) benefit from incentives from EMA for their develop-
ment, but in a context of economical restrictions payers are more and more worried by 
highly priced medicines. The aim of this research was to evaluate whether the orphan 
designation has an impact on the reimbursement and pricing for drugs in oncology 
in European coutries. METHODS: First, a literature review was performed to identify 
specific methodologies or consideration applied for the evaluations of ODs. Second, 
a comparative analysis of HTA recommendations for drugs registered for their first 
indication in oncology between 2006 and 2013 and appraised by four agencies (HAS, 
G-BA, NICE, SMC) was performed, as well as coverage decisions, treatment cost, and 
delay between approval and price agreement. RESULTS: In the selected countries, 
there is no specific methods to assess ODs. However some special considerations are 
made to accept higher level of uncertainty. 49 drugs were included in the analysis. 
Significant inter-country variability in the HTA recommendations exists: 20% of drugs 
received heterogeneous recommendations across countries. The highest concordance 
scores were obtained between NICE and SMC for ODs (0.9 kappa score), for others con-
cordance was poor. The percentage of rejection for ODs was not higher than the one 
for non-ODs. Average treatment costs were in favour of orphan oncology drugs, still 
it was not significant. There was correlation between treatment cost and population 
size for the non-ODs, but it was not the case for ODs. Delay of appraisal for ODs was 
slightly shorter, but never significant, except for NICE. CONCLUSIONS: In this study 
we did not show a significant advantage or disadvantage in the market access of ODs 
in oncology. However, as more ODs will obtain regulatory approval on an accelerated 
or conditional licensing, providing expanded evidence package to show the value for 
money to payer will become harder.
